These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35094254)

  • 1. Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases.
    Sieber A; Aberra FN; Bonhomme B; McKeever L; Lewis JD
    Dig Dis Sci; 2022 Nov; 67(11):5168-5176. PubMed ID: 35094254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease.
    George J; Singh S; Dulai PS; Ma C; Nguyen T; Feagan BG; Sandborn WJ; Jairath V
    Inflamm Bowel Dis; 2020 Mar; 26(4):515-523. PubMed ID: 31504528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
    Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Biologic Treatment Decreases Risk of Surgery in Crohn's Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis.
    Law CCY; Tkachuk B; Lieto S; Narula N; Walsh S; Colombel JF; Ungaro RC
    Inflamm Bowel Dis; 2024 Jul; 30(7):1080-1086. PubMed ID: 37506265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
    Hirayama D; Hyodo S; Morita K; Nakase H
    J Gastroenterol; 2024 May; 59(5):389-401. PubMed ID: 38492011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
    Cai Q; Ding Z; Fu AZ; Patel AA
    BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
    Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
    Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
    Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies.
    Macaluso FS; Ventimiglia M; Orlando A
    J Crohns Colitis; 2023 Aug; 17(8):1217-1227. PubMed ID: 36913311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis?
    Larsen MD; Nørgård BM; Kjeldsen J
    Inflamm Bowel Dis; 2022 Nov; 28(11):1658-1666. PubMed ID: 34977919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends and demographic patterns in biologic and corticosteroid prescriptions for inflammatory bowel disease: findings from electronic medical records, 2011-2020.
    Xu F; Liu Y; Greenlund K; Carlson S
    J Investig Med; 2022 Dec; 70(8):1771-1776. PubMed ID: 36455956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
    Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort.
    Kaplan JL; Liu C; King EC; Bass JA; Patel AS; Tung J; Chen S; Lissoos T; Candela N; Saeed S; Colletti RB;
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):566-575. PubMed ID: 36804501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
    Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
    BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.